CorMedix Seizes Heron Assets to Boost Acute‑Care Profits & Shareholder ValueCorMedix boosts its acute‑care portfolio with a $145 M Heron Therapeutics acquisition, adding high‑growth products and $45‑$60 M synergies.CORMEDIX INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 10/11/2026, 14:03 2 minutes to read